Roche and Genentech Invest US$700 Million for State-of-the-Art Manufacturing Facility in North Carolina, USA
Introduction:
Roche and Genentech plan to invest US$700 million in the development of a cutting-edge drug manufacturing facility in Holly Springs, North Carolina, USA.
Features:
The planned 700,000-square-foot facility in Holly Springs, North Carolina, is intended to support the manufacturing of metabolic medicines, including treatments for obesity.
Designed as a multipurpose manufacturing site, it will include areas for drug substance production, drug product formulation, analytical testing, and controlled storage.
The layout will incorporate modular cleanroom environments to accommodate varying production scales and future technology upgrades.
Systems for aseptic processing, containment, and environmental monitoring will be implemented to align with current Good Manufacturing Practice (GMP) requirements.
Integrated digital infrastructure will be used to support process automation, data tracking, and real-time quality monitoring.
Facilities for quality control, utilities management, waste handling, and material logistics will be included to enable end-to-end manufacturing activities.
The site will be equipped with standard utility systems, such as water for injection (WFI), heating, ventilation, air conditioning (HVAC), and power backup, designed for uninterrupted operation.
Specifications:
| Name | Roche and Genentech |
| Type | New Construction |
| Budget | US$700 Million |
| Year | TBD |
